The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development. Issue 1 (31st December 2023)

• Record Type: Journal Article
• Authors: Yu, Haiyun; Guan, Fei; Miller, Heather; Lei, Jiahui; Liu, Chaohong
• Is Part Of: Emerging microbes & infections. Volume 12:Issue 1(2023)
• Publication Date: 2023-12-31
• Subjects: SARS-CoV-2 -- nucleocapsid -- inflammation -- cell death -- innate immunity -- adapted immunity -- vaccine; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2164219
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT : The coronavirus disease 2019 (COVID-19) has caused enormous health risks and global economic disruption. This disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 nucleocapsid protein is a structural protein involved in viral replication and assembly. There is accumulating evidence indicating that the nucleocapsid protein is multi-functional, playing a key role in the pathogenesis of COVID-19 and antiviral immunity against SARS-CoV-2. Here, we summarize its potential application in the prevention of COVID-19, which is based on its role in inflammation, cell death, antiviral innate immunity, and antiviral adaptive immunity.